Medizinisches Cannabis kann als zusätzliche Therapieoption verschrieben werden, aber die Evidenzlage ist dünn und eine Zweckentfremdung oft nicht ausgeschlossen. Doch mit dem Schattendasein soll jetzt ...

Aurora Cannabis (ACB) is pleased to announce the company’s discovery of a novel source of genetic resistance against powdery mildew, PM2, that ...

Shares of Aurora Cannabis Inc. ACB rallied 5.30% to $4.57 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.33% to ...

Has Aurora Cannabis Inc. (ACB) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer ...

Aurora Cannabis produces and sells a variety of cannabis products, including dried cannabis, oils, capsules, and topical treatments, primarily for medical patients. It also manufactures and sells ...

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good investment right now? Aurora Cannabis produces and sells a variety of ...

Aurora Cannabis (TSX:ACB) announced the discovery of PM2, a new source of genetic resistance for cannabis plants against ...

Aurora Cannabis has transformed its margins, market position, and balance sheet over the last few years, and the stock is now highly 'investible'. ACB's strategic focus on the global medical ...

Shares of Aurora Cannabis Inc. (ACB) have gained 50.8% over the past four weeks to close the last trading session at $5.61, but there could still be a solid upside left in the stock if short-term ...